Diasorin Introduces in the US Market the Aldosterone Assay on its Liaison Platforms and Expands Further its Current US Menu with Additional Products

The Italian Company is the only supplier of the test in the U.S. market on CLIA technology

April 17, 2013 - Saluggia (VC) - Diasorin (FTSE MIB:DIA), the Italian international leader in biotechnology, which for over 40 years, develops, manufactures and globally markets reagent kits for in vitro diagnostics, strengthens its menu offer in the US market with the approval by the Food and Drug Administration to market the Aldosterone assay on the Liaison family in the US.

Aldosterone is a mineralocorticoid hormone produced by the adrenal cortex. Its function is to increase sodium reabsorption in the kidneys. The test is primarily used for the diagnosis of hypertension, one of the most common diseases in the world and the primary cause of many of the cardiac ischemic and cerebral events, today the leading cause of permanent disability and death in the world.

The approval of this product is an important step in the Diasorin menu expansion, since the Italian Company is the only supplier of the test on a CLIA platform in the US market.
Moreover, the addition of the new Aldosterone assay to the Liaison analyzer menu and its combination with the Direct Renin assay, positions Diasorin as the only player in the hypertension market, able to provide its customers with the opportunity to complete the “Hypertension panel”, and consolidate the broadest Bone & Mineral and Endocrinology menus on a single fully automated system, with unique assays and recognized high quality.

According to Francesco Colotta, Chief Medical Officer of the Group, “The therapeutic treatment of hypertension is based on the accuracy of the diagnosis. There are several forms of hypertension, some of which are characterized by high levels of Aldosterone. The availability of a simple, automated and accurate assay for the determination of the Aldosterone, provides to the medical community a further tool to approach correctly the hypertension”.

Diasorin also received the FDA approval for two other products, TSH and fT4, which enrich the current offer of the Endocrinology family on the Liaison analyzers, thus implementing the expansion of its menu in the US market and pursuing a more and better competitive positioning.

Today there are 30 assays available on the Liaison platforms in the United States.

Carlo Rosa, CEO of the Diasorin Group, commented, “Our strategy to expand our menu in the US market continues through these new significant developments, by leveraging on our strong historical positioning and installed base in the market, achieved thanks to our Vitamin D. The Aldosterone test is strategic for Diasorin, because it completes our offer in the hypertension market where we plan to become a leader in the future, as we did in the bone & mineral disease clinical area”.

Moreover, according to Mr. Rosa “The approval obtained for TSH and fT4 assays, which complete our Endocrinology panel, is strategic in order to position our Liaison platform also in the hospital segment, allowing us to become leaders with our new specialty tests and, at the same time, to give our clients a complete automatic solution also for their routine tests”.

Press Release
The Hypertension in the world is the third leading cause of death after malnutrition and diseases related to smoking. According to the WHO hypertension affects 20% of the population. In Italy, according to the study "RIFLE", conducted in 13 regions on seventy thousands subjects aged between 20 and 69 years, the prevalence of hypertension varies from 21.3% to 25.7% and the prevalence increases with the increase of age to over 30% in the elderly. Furthermore most recent epidemiological studies show increasing prevalence values than those found in previous years.

For additional information, please contact:

Riccardo Fava
External Relations Director - Head of IR and Media
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Margherita Sacerdoti
Investor Relations Specialist
Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it